Candel therapeutics and partnership for accelerating cancer therapies (pact) to collaborate on lung cancer trial for can-2409

Needham, mass., dec. 10, 2021 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced a collaboration with partnership for accelerating cancer therapies (pact) and the cancer immune monitoring and analysis centers – cancer immunologic data commons (cimac-cidc) to profile the biomarker response to a combination of can-2409 + valacyclovir in combination with anti-pd-1 and pd-l1 immune checkpoint inhibitors in patients with non-small cell lung cancer (nsclc).
CADL Ratings Summary
CADL Quant Ranking